UK biotech CellVoyant appoints Brand2Life to launch its brand to market

London, 16^th February, 2024 – Brands2Life has been appointed by Bristol University spin-out CellVoyant to raise brand awareness among potential customers, investors and talent and to communicate its mission to accelerate the development of cell therapies with AI.

Cell therapies hold the potential to revolutionise treatments for diseases such as cancer, diabetes and age-related macular degeneration. However, they are very challenging and expensive to develop and manufacture. CellVoyant’s AI-first technology platform makes it possible to monitor and forecast the behaviour of live cells, enabling the development of novel cell therapies, better, faster, and more cost-effectively.

CellVoyant’s programme with Brands2Life begins with the launch of its seed funding before evolving into an ongoing thought leadership and executive profiling programme across earned media, owned channels and events, to position its spokespeople as experts in the development of cell therapies.

Rafael E. Carazo Salas, CEO and founder of CellVoyant said: “We have spent the last two years building this truly groundbreaking technology at our labs in Bristol, so we needed to be sure our first agency partner could help bring us to market with maximum impact.

“We chose to work with Brands2Life because the team demonstrated an excellent understanding of the cell therapy and wider biotech market; showed practical insight into the challenges and ambitions of university spin-out founders; has an array of contacts and knowledge across the media; and most importantly, has the ability to help us communicate the potential that our technology can have on saving lives. The team also shows genuine passion for our work which has led to great chemistry between us.”

Kate Smith, Deputy MD of Business & Technology and Life Sciences lead, said: “From the moment we met Rafael and his team, the partnership felt like a natural fit for Brands2Life; CellVoyant is not only a brand transforming our world, it’s transforming our health and our lives, and the fact that such a fascinating biotech company is founded here in the UK makes us even more excited to tell its story. We can’t wait to help build CellVoyant’s profile in the media and beyond.”

CellVoyant joins Brands2Life’s growing life sciences, biotech and health and wellbeing ecosystem of clients including Benchling, CooperVision, Sanofi, Hoxton Farms and Veeva Systems.